Allievex

Recent Finacing

Series A

Recent Raise

Undisclosed

Allievex is a clinical-stage biotechnology company developing tralesinidase alfa, an IGF2‑tagged recombinant NAGLU enzyme replacement for treating Sanfilippo syndrome type B, under an exclusive license from BioMarin.

Founded 2018

Massachusetts, United States

11-50

Private

allievex.com

Highlights

Focus Areas

Biotechnology

Recent Investors

Financials

1

Funding round

2

Investors

Team

Upgrade to view the team

See the team members at Allievex.